Home / Publications / New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus

New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus

Mikhail Stanislavovich Novikov 1
Mikhail Stanislavovich Novikov
, 
Maria Petrovna Paramonova 1
Maria Petrovna Paramonova
, 
Ilia M Kirillov 2
Ilia M Kirillov
, 
Olga Aleksandrovna Smirnova 3
Olga Aleksandrovna Smirnova
, 
Anastasia Lvovna Khandazhinskaya 3
Anastasia Lvovna Khandazhinskaya
, 
Alexander Olegovich Chizhov 4
Alexander Olegovich Chizhov
, 
Sergei Nikolaevich Kochetkov 3
Sergei Nikolaevich Kochetkov
, 
Alexander Vladimirovich Ivanov 3
Alexander Vladimirovich Ivanov
, 
Irina F Fedyakina 2
Irina F Fedyakina
1 Volgograd State Medical University, Volgograd, Russian Federation
2 N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russian Federation
3 V.A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation
10.1016/j.mencom.2023.06.031
Published 2023-06-13
Communication , Volume 33, Issue 4, 537-538
2
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Novikov M. S. et al. New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus // Mendeleev Communications. 2023. Vol. 33. No. 4. pp. 537-538.
GOST all authors (up to 50) Copy
Novikov M. S., Paramonova M. P., Kirillov I. M., Smirnova O. A., Khandazhinskaya A. L., Chizhov A. O., Kochetkov S. N., Ivanov A. V., Fedyakina I. F. New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus // Mendeleev Communications. 2023. Vol. 33. No. 4. pp. 537-538.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2023.06.031
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.031
TI - New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus
T2 - Mendeleev Communications
AU - Novikov, Mikhail Stanislavovich
AU - Paramonova, Maria Petrovna
AU - Kirillov, Ilia M
AU - Smirnova, Olga Aleksandrovna
AU - Khandazhinskaya, Anastasia Lvovna
AU - Chizhov, Alexander Olegovich
AU - Kochetkov, Sergei Nikolaevich
AU - Ivanov, Alexander Vladimirovich
AU - Fedyakina, Irina F
PY - 2023
DA - 2023/06/13
PB - Mendeleev Communications
SP - 537-538
IS - 4
VL - 33
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Novikov,
author = {Mikhail Stanislavovich Novikov and Maria Petrovna Paramonova and Ilia M Kirillov and Olga Aleksandrovna Smirnova and Anastasia Lvovna Khandazhinskaya and Alexander Olegovich Chizhov and Sergei Nikolaevich Kochetkov and Alexander Vladimirovich Ivanov and Irina F Fedyakina},
title = {New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus},
journal = {Mendeleev Communications},
year = {2023},
volume = {33},
publisher = {Mendeleev Communications},
month = {Jun},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.031},
number = {4},
pages = {537--538},
doi = {10.1016/j.mencom.2023.06.031}
}
MLA
Cite this
MLA Copy
Novikov, Mikhail Stanislavovich, et al. “New N1-(4-aryloxybenzyl)uracils containing N3-positioned 4-(trimethyleneoxy)benzoic acid moiety, and study of their antiviral activity against SARS-CoV-2 and influenza virus.” Mendeleev Communications, vol. 33, no. 4, Jun. 2023, pp. 537-538. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2023.06.031.

Keywords

antiviral activity
benzoic acid derivatives
N-alkylation.
SARS-CoV-2
uracil derivatives

Abstract

New title uracil derivatives, 4-{3-[2,6-dioxo-3-(4-aryl-oxybenzyl)-3,6-dihydropyrimidin-1(2H)-yl]propoxy}benzoic acids and their butoxy homologues, were obtained in three steps using 2,4-bis(trimethylsilyloxy)pyrimidine, 4-aryloxy-benzyl bromides and methyl 4-(ω-bromoalkoxy)benzoates as the key reactants. The compounds were studied as inhibitors of H1N1 influenza virus and SARS-CoV-2 R replication in MDCK and Vero E6 cell cultures, respectively, which revealed that the tested compounds had high levels of anti-SARS-CoV-2 activity.

References

.
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schäfer A., Dinnon K.H., Stevens L.J., Chappell J.D., Lu X., Hughes T.M., George A.S., Hill C.S., et. al.
Science Translational Medicine, 2020
.
Matyugina E.S., Novikov M.S., Kozlovskaya L.I., Volok V.P., Shustova E.Y., Ishmukhametov A.A., Kochetkov S.N., Khandazhinskaya A.L.
Acta Naturae, 2021
.
Scaffold hopping: Exploration of acetanilide-containing uracil analogues as potential NNRTIs
Babkov D.A., Valuev-Elliston V.T., Paramonova M.P., Ozerov A.A., Ivanov A.V., Chizhov A.O., Khandazhinskaya A.L., Kochetkov S.N., Balzarini J., Daelemans D., Pannecouque C., Seley-Radtke K.L., Novikov M.S.
Bioorganic and Medicinal Chemistry, 2015
.
1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyluracils as potent anti-HIV-1 agents
Novikov M.S., Ivanova O.N., Ivanov A.V., Ozerov A.A., Valuev-Elliston V.T., Temburnikar K., Gurskaya G.V., Kochetkov S.N., Pannecouque C., Balzarini J., Seley-Radtke K.L.
Bioorganic and Medicinal Chemistry, 2011
.
Toward the discovery of dual HCMV–VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides
Babkov D.A., Khandazhinskaya A.L., Chizhov A.O., Andrei G., Snoeck R., Seley-Radtke K.L., Novikov M.S.
Bioorganic and Medicinal Chemistry, 2015
.
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski P., Kratzel A., Steiner S., Stalder H., Thiel V.
Nature Reviews Microbiology, 2020
.
Paramonova M.P., Ozerov A.A., Chizhov A.O., Snoeck R., Andrei G., Khandazhinskaya A.L., Novikov M.S.
Mendeleev Communications, 2019
.
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19
Yadav R., Chaudhary J.K., Jain N., Chaudhary P.K., Khanra S., Dhamija P., Sharma A., Kumar A., Handu S.
Cells, 2021
.
Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern
Siniavin A.E., Novikov M.S., Gushchin V.A., Terechov A.A., Ivanov I.A., Paramonova M.P., Gureeva E.S., Russu L.I., Kuznetsova N.A., Shidlovskaya E.V., Luyksaar S.I., Vasina D.V., Zolotov S.A., Zigangirova N.A., Logunov D.Y., et. al.
International Journal of Molecular Sciences, 2022
.
Older adults with SARS‐CoV‐2 infection: Utility of the clinical frailty scale to predict mortality
Gilis M., Chagrot N., Koeberle S., Tannou T., Brunel A., Chirouze C., Bouiller K.
Journal of Medical Virology, 2021
.
In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
Szemiel A.M., Merits A., Orton R.J., MacLean O.A., Pinto R.M., Wickenhagen A., Lieber G., Turnbull M.L., Wang S., Furnon W., Suarez N.M., Mair D., da Silva Filipe A., Willett B.J., Wilson S.J., et. al.
PLoS Pathogens, 2021
.
Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication
Magri A., Ozerov A.A., Tunitskaya V.L., Valuev-Elliston V.T., Wahid A., Pirisi M., Simmonds P., Ivanov A.V., Novikov M.S., Patel A.H.
Scientific Reports, 2016
.
Paramonova M.P., Snoeck R., Andrei G., Khandazhinskaya A.L., Novikov M.S.
Mendeleev Communications, 2020
.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., Du J., Pedley A., Assaid C., Strizki J., Grobler J.A., et. al.
New England Journal of Medicine, 2021
.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., Pypstra R., Rusnak J.M.
New England Journal of Medicine, 2022
.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., Hidalgo A., Sachdeva Y., Mittal S., Osiyemi O., Skarbinski J., et. al.
New England Journal of Medicine, 2021